Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 58 min 37 sec ago

Aeterna Zentaris Announces At the Market Issuance Program

4 hours ago
CHARLESTON, S.C.--(BUSINESS WIRE)--#AEZS--Aeterna Zentaris Announces at the Market Issuance Program

Bio-economy Report Indicates Wage Subsidy Programs Play Important Economic Role

12 hours 1 min ago
OTTAWA, Ontario--(BUSINESS WIRE)--#HR--New report indicates wage subsidy programs critical for the growth and development of small- and medium-sized businesses within Canada’s bio-economy, and for new graduates.

Biogen to Present Data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases

13 hours 2 min ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen to Present Data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases.

Generex Announces Featured Presentation of Cancer Immunotherapy Developed by Subsidiary at OPT Boston

Mon, 27/03/2017 - 09:24
MIRAMAR, FL--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTC Pink:GNBTD) today announced that Dr. Eric von Hofe, Ph.D., President of the Company’s wholly-owned immuno-therapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be a featured speaker at the Cambridge Healthtech Institute’s second annual Oligonucleotide & Peptide Therapeutics conference (OPT Boston) (www.optcongress.com) being held in Cambridge, MA March 27 – 29, 2017. OPT Boston has been established

Aurinia Highlights 48-Week Data from Open-Label AURION Study at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017)

Mon, 27/03/2017 - 04:22
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the 48-week results from the “Aurinia Early Urinary Protein Reduction Predicts Response Study” (AURION) open-label study of voclosporin for the treatment of lupus nephritis (LN) at the 12th International Congress on Systemic Lupus Erythematosus and 7th Asian Congress on

Therapure Biomanufacturing Receives 2017 CMO Leadership Individual Attribute Awards for Capabilities and Staff Characteristics

Thu, 23/03/2017 - 13:00
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Therapure Biomanufacturing, the contract development and manufacturing division of Therapure Biopharma Inc., announces that it has received The CMO Leadership Individual Attribute awards in four areas: Strength of Science, State of the Art, Accessible Senior Management and Cultural Fit. The Life Science Leader’s annual CMO Leadership Awards Ceremony was held March 22, 2017 in New York City with winners chosen based on Industry Standard Research’s (ISR’s) B

Life Sciences Ontario Strengthens its Leadership with New Chair, Board Members

Thu, 23/03/2017 - 13:00
TORONTO--(BUSINESS WIRE)--Life Sciences Ontario announces a new Chair of its Board of Directors and two new Board Members, strengthening its capacity to foster growth and commercialization in Ontario’s life sciences sector.

Synaptive Medical Expands Medtech Expertise Through Board Additions

Thu, 23/03/2017 - 09:59
TORONTO--(BUSINESS WIRE)--#MedDevice--Synaptive Medical Expands Medtech Expertise Through Board Additions

Montreal’s Intelerad Medical Systems Signs Major Deal with Leading Australian Healthcare Provider

Thu, 23/03/2017 - 08:58
MONTREAL--(BUSINESS WIRE)--Intelerad Medical Systems™, a leader in medical imaging software solutions, today announced that Australia’s Primary Health Care Limited (Primary) has selected Intelerad’s medical imaging platform, InteleOne® XE, for archiving, displaying and sharing diagnostic images. The platform will enable Primary’s 141 diagnostic imaging locations to operate as a unified entity. One of Australia’s largest diagnostic imaging networks, Primary’s Healthcare Imaging Services (HIS) pr

InVivo to Initiate Cervical Spinal Cord Injury Study

Thu, 23/03/2017 - 08:58
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that Health Canada has approved the company’s Investigational Testing Authorization application to commence a clinical study of the Neuro-Spinal Scaffold™ in patients with acute, complete (AIS A) cervical (C5-T1) spinal cord injuries (SCIs). InVivo currently is in late stage conversation with several site Research Ethics Boards and expects to announce its first Canadian site in the coming weeks. “This a

BIOTECanada: Federal Budget Strengthens Biotechnology Industry Ecosystem Building Canadian Economy

Wed, 22/03/2017 - 21:56
OTTAWA, Ontario--(BUSINESS WIRE)--Canada's biotech industry today welcomed the federal budget and its measures supporting the advancement of Canadian innovation in biotechnology centered sectors such as health/bio-sciences, clean technology and agri-food. Importantly the budget proposes support for the acceleration of innovation through the establishment of sector specific superclusters, including health/bio-sciences, agri-food and clean technology. "The core of our industry is innovation - muc

Primary Health Care Limited (Primary) Signs Deal to Deploy Intelerad Medical Imaging Software Platform

Wed, 22/03/2017 - 17:56
MONTREAL--(BUSINESS WIRE)--Highlights: Primary operates 141 diagnostic imaging locations across Australia (public hospitals, private hospitals, medical centres and community-based centres) Intelerad’s medical imaging platform will be used for diagnostic reporting, collaboration and archive of medical images The platform will enable Primary’s 141 diagnostic imaging locations to operate as a unified entity Intelerad is a market leader in Australia – new deal gives them an estimated 85% share of t

BIO Announces Plenary Sessions for 2017 World Congress on Industrial Biotechnology

Wed, 22/03/2017 - 12:54
WASHINGTON--(BUSINESS WIRE)--BIO today released the list of speakers for plenary programs at the 2017 World Congress on Industrial Biotechnology. The world’s largest industrial biotech event will be held July 23-26, 2017.

AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Gaucher Disease

Wed, 22/03/2017 - 08:53
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AvroBio, Inc. expands rare disease pipeline with gene therapy to treat Gaucher disease. The program has achieved preclinical proof of concept and IND-enabling activities are underway.

CanniMed Therapeutics Inc. Receives Two Export Permits from Health Canada and Initial Purchase Orders for Distribution to Australia and the Cayman Islands

Wed, 22/03/2017 - 07:53
SASKATOON, Saskatchewan--(BUSINESS WIRE)--CanniMed Therapeutics Inc. Receives Export Permit for Australia and Cayman Island Distribution of medical cannabis from Health Canada

ZOLL Receives Health Canada Approval for Two New Models Of AEDS

Tue, 21/03/2017 - 13:48
CHELMSFORD, Mass.--(BUSINESS WIRE)--#AEDs--ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that Health Canada has approved the ZOLL AED 3™* and the ZOLL AED 3™ BLS* (basic life support) automated external defibrillators for marketing and distribution in Canada. These new AEDs continue ZOLL’s tradition of providing best-in-class AEDs to help improve outcomes for cardiac arrest patients. Both the ZOLL AED 3 and the

Aurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

Mon, 20/03/2017 - 16:43
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the closing of its previously announced underwritten public offering of 25,645,000 common shares, including 3,345,000 common shares pursuant to the full exercise of the underwriters’ option to purchase additional common shares (the “Offering”). The shares were sold at a

LMC Announces New Diabetes & Endocrinology Specialist Clinic in Ottawa

Mon, 20/03/2017 - 09:43
OTTAWA, Ontario--(BUSINESS WIRE)--#Diabetes--LMC, North America’s largest specialist care provider in diabetes and endocrinology, announced today that it will be opening its newest clinic in April 2017 to better serve the Ottawa region. The new LMC Ottawa clinic will be the practice home for four active Ottawa Endocrinologists: Dr. Nadia Malakieh, Dr. Timothy O’Leary, Dr. Patricia Peticca and Dr. Chetna Tailor. Endocrinologists are specialists who treat patients with conditions that result from hormone im

Ferring and CDI sign agreement granting Ferring exclusive marketing rights to VSL#3® in Europe and Canada

Mon, 20/03/2017 - 06:42
SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals and CD Investments (CDI) announced today that they have signed an agreement granting Ferring exclusive European marketing rights to CDI’s VSL#3®. This agreement extends Ferring’s existing rights to market the product in the UK, Italy and Canada. VSL#3® is a food supplement, containing 450 billion live bacteria in eight different strains per sachet, which colonizes the gut and benefits from a unique formulation. Research has confi

CanniMed Therapeutics Inc. Corrects Previously Released Q1 Average Selling Prices

Fri, 17/03/2017 - 10:11
SASKATOON, Saskatchewan--(BUSINESS WIRE)--CanniMed Therapeutics Inc. Corrects Previously Released Q1 Average Selling Prices

Pages